Daniel Blumer, DO
Family Medicine · Canton, OHNPI 1598707770
Payments from drug & device makers
Across 779 payments — averaging $14.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Boehringer Ingelheim$1K
- Pfizer$1K
- Novo Nordisk$1K
- AbbVie$975
- GSK$947
- plus $3K from 28 others
What the payments were for
- Food & beverage$10,76999%
- Education$1471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 88 | $2,463 |
| Boehringer Ingelheim | 109 | $1,185 |
| Pfizer | 92 | $1,073 |
| Novo Nordisk | 98 | $1,051 |
| AbbVie(2 entities) | 82 | $975 |
| GSK | 81 | $947 |
| Lilly USA, LLC | 54 | $695 |
| Amarin Pharma, Inc. | 37 | $390 |
| Astellas Pharma US Inc | 15 | $288 |
| Johnson & Johnson | 15 | $229 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $204 |
| Sanofi-aventis U.S. LLC | 12 | $168 |
| Merck | 10 | $156 |
| Biohaven Pharmaceuticals, Inc. | 14 | $154 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $139 |
| Amgen | 6 | $107 |
| Kowa Pharmaceuticals America, Inc. | 6 | $100 |
| Verona Pharma, Inc. | 4 | $90 |
| Xeris Pharmaceuticals, Inc. | 4 | $70 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Bayer | 3 | $56 |
| Sumitomo Pharma America, Inc. | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 3 | $42 |
| Amneal Pharmaceuticals LLC | 2 | $34 |
| Novartis | 2 | $33 |
| Exact Sciences | 1 | $25 |
| Intersect ENT, Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $19 |
| Grifols USA, LLC | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Abbott | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,210
- BREZTRI$827
- SYMBICORT$428
- BREZTRI AEROSPHERE$138
- AIRSUPRA$138
- BEVESPI AEROSPHERE$125
How this compares
$10,916 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 159 | $153,235 |
| FarxigaDapagliflozin Propanediol | 120 | $150,897 |
| OzempicSemaglutide | 90 | $121,380 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 130 | $101,173 |
| EliquisApixaban | 112 | $85,085 |
| TrulicityDulaglutide | 61 | $66,365 |
| TradjentaLinagliptin | 38 | $35,922 |
| JanuviaSitagliptin Phosphate | 24 | $31,086 |
| XareltoRivaroxaban | 19 | $29,541 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $24,642 |
| Nurtec OdtRimegepant Sulfate | 11 | $22,641 |
| MyrbetriqMirabegron | 29 | $22,240 |
| Spiriva RespimatTiotropium Bromide | 23 | $17,161 |
| EntrestoSacubitril/Valsartan | 12 | $13,874 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $12,826 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Jentadueto, Synjardy Xr | $1,185 | $215,848244 claims |
| AstraZenecaFarxiga | $2,463 | $150,897120 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $947 | $121,753164 claims |
| Novo NordiskOzempic | $1,051 | $121,38090 claims |
| PfizerEliquis, Nurtec Odt | $1,073 | $107,726123 claims |
| Lilly USA, LLCTrulicity | $695 | $66,36561 claims |
| MerckJanuvia, Belsomra | $156 | $36,00635 claims |
| Johnson & JohnsonXarelto | $229 | $29,54119 claims |
| Astellas Pharma US IncMyrbetriq | $288 | $22,24029 claims |
| NovartisEntresto | $33 | $13,87412 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $34 | $4,616521 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Canton
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.